Several uncontrolled studies have encouraged the use of rituximab (RTX) in patients with myositis. Unfortunately, the first placebo-phase trial to assess the efficacy of RTX in refractory myositis did not show a significant difference between the two treatment groups, and doubts have been expressed about its study design. In this review we present an up-to-date overview of the reported experiences of RTX therapy in myositis. A PubMed search was performed to find all the available cases of refractory myositis patients treated with RTX up to July 2015. The following terms were assessed: inflammatory myopathies OR anti-synthetase syndrome OR polymyositis OR dermatomyositis AND RTX. A total of 48 studies were included. We identified 458 patients with myositis treated with RTX. We found a rate of response to RTX of 78.3%. RTX can play a role in the management of patients with myositis, at least in those with positive myositis-specific autoantibodies.
Introduction
The idiopathic inflammatory myopathies (IIMs) are a group of acquired, heterogeneous, systemic diseases of skeletal muscle, including adult PM, adult DM, JDM, juvenile PM (JPM), anti-synthetase syndrome (ASS) and IBM. Features common to all of these subtypes include muscle weakness, elevated serum levels of muscle enzymes, myopathic abnormalities on electromyography and inflammatory cell infiltrates on muscle biopsy. However, each subset has distinct clinical, histological and immunepathological characteristics. Both DM and PM usually present with symmetrical and proximal muscle involvement, but in DM typical skin lesions can also occur. IBM is predominantly characterized by weakness and atrophy of distal muscles, especially wrist and finger flexors.
As these conditions are rare, current treatment of myositis is based mainly on case reports and a few randomized controlled trials with small numbers of patients enrolled. As a result, the choice of treatment is often empirical. The general clinical consensus among physicians is to use high-dose CS therapy as the first-line option in patients with myositis. In order to avoid side effects, the prednisolone dose should be reduced based on patient's clinical response [1] . However, several patients discontinue steroid treatment early because of a lack of improvement and/or adverse events [2] . In clinical practice, an immunosuppressive drug is often added as a steroidsparing agent or in CS-resistant patients or when disease relapses. Nevertheless, a Cochrane review concluded that there was insufficient evidence from the available studies to confirm the value of immunosuppressive agents in myositis [3] .
For refractory DM, IVIG had short-term clinical efficacy in a double-blind, placebo-controlled trial [4] . However, long-term safety and efficacy need to be tested. IVIG can also be effective in some difficult-to-treat patients with PM [5] , but offers only partial and short-lived benefit to a small number of cases with IBM, which is refractory to most therapies [6] . CYC and tacrolimus might be useful, especially in patients with interstitial lung disease (ILD) and severe myopathy [6, 7] .
In patients with myositis resistant to conventional treatment, rituximab (RTX) is a potential treatment option. RTX is a chimeric monoclonal antibody binding the CD20 antigen expressed on the surface of B lymphocytes at most stages of their development, but not on pro-B cells, early pre-B cells and plasma cells. It results in rapid depletion of CD20-positive B lymphocytes from the peripheral blood for up to 69 months [8] . Although beneficial effects of RTX have been suggested by case reports and case series, the experience in adult and paediatric patients with refractory myositis is limited. The determination of which subset(s) of patients is/are more likely to be responsive, when RTX should be administered during the disease course, whether to use combination therapies and the optimal regimen and schedule for re-treatment, remain to be elucidated.
In this study we review the most significant published data regarding the use of RTX for patients with PM and DM and try to identify which group of patients might be the most likely to benefit from this treatment.
Search strategy
We analysed current evidence on the therapeutic use of RTX in refractory patients with IIM by a review of the literature, including articles published up to July 2015. This review was based on a bibliographic search in the PubMed database, using the following keywords: inflammatory myopathies OR anti-synthetase syndrome OR polymyositis OR dermatomyositis AND rituximab. Furthermore, we also included some relevant studies not present in our PubMed search, but referenced in other articles.
We considered case reports and open label studies, as defined by the authors. We also subdivided case series papers into moderate/large if they had four or more cases or small if they had less than four subjects.
A total of 48 articles were identified (Table 1) . In particular, we found 19 case reports, 4 open label studies, 24 case series (8 small, 16 moderate/large series) and the RTX in Myositis (RIM) trial [9] . The general characteristics and responses of patients with IIM to RTX therapy are shown in Table 1 . The papers are reported in the table according to the chronological order of publishing.
Review of patients treated with RTX
In total, we identified 458 patients with IIM treated with RTX. DM was the most frequent disease reported [151 cases (32.9%)]. The response to RTX in refractory PM has been analysed in 144 patients (31.4%), including 19 subjects with anti-signal recognition particle antibody positivity. In addition, RTX was administered to 79 patients with ASS (17.2%) and to 72 patients with JDM (15.7%). One patient each was affected with IBM and undifferentiated inflammatory myositis (UI). In 10 cases, the IIM subtype was not specified.
The most frequent refractory symptom for which the RTX was administered was muscle weakness (411/458; 89.7%). There was some heterogeneity in the RTX regimen used. The majority of the patients that we reviewed (193/458; 42.1%) received the protocol widely used for RA (two infusions at a dose of 1000 mg of RTX, given 2 weeks apart). (Table 1) Several reports supported the beneficial effects of CD20 depletion therapy in refractory ILD. In the pilot study of Levine [10] , a clinical response was observed in two antiJo1positive patients with pulmonary involvement after RTX therapy. In 2009, a retrospective case series [11] reported a significant improvement on high-resolution CT imaging and/or pulmonary function tests (PFTs) in 7 out of 11 ASS patients with ILD, following 6 months of RTX. However, the main concern with these studies is the use of several immunosuppressive agents both prior to and following treatment with RTX. Subsequently, Marie et al. [37] published results of seven anti Jo-1positive patients with refractory ILD treated with RTX in combination only with steroids. After a year, all seven patients had amelioration or resolution of their pulmonary symptoms and significant improvement in PFTs and high-resolution CT findings.
A retrospective study analysed 50 patients with severe ILD (progressing despite conventional immunosuppression) treated with RTX [53] ; of these, 33 had ILD associated with CTD. B cell depletion was effective as rescue therapy, stabilizing and/or improving the pulmonary function in 36 of the 50 patients (72%). Interestingly, within the CTDILD cohort, patients with myositis were most likely to improve in PFTs (forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DL CO )], following RTX therapy. To avoid potential effects of thoracic muscle weakness on the PFTs, Unger et al. [50] analysed the total lung capacity improvement. Again, six of eight patients responded and total lung capacity was stable in the other two patients. Interestingly, data from a 52-month follow-up study [52] showed that www.rheumatology.oxfordjournals.org
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Rituximab in the treatment of inflammatory myopathies: a review the most beneficial effects on lung function were observed in patients with disease duration <1 year and acute onset of ILD. RTX was generally well tolerated. The most common side effects were infections (mainly respiratory tract infections), of which 5% were severe, requiring hospitalization. Infusion reactions rarely occurred; they were often mild and easily controlled with steroids.
Consideration of RTX's current role in the treatment of myositis
Due to the rarity and heterogeneity of IIMs, the main concern with their treatment is the lack of adequate controlled trials, with only partially validated outcome measures. RTX was empirically used off-label in patients who did not show a good response to the conventional therapy. The reasons for trying this approach were based on the evidence of circulating autoantibodies in up to 80% of patients with IIM [23] and on the presence of B cells in the perivascular region of muscles in patients with DM and in the inflammatory muscle fibres in both PM and DM patients [56] . Given the likely pathogenetic role of B cells in myositis and the favourable data from B cell depleting therapy from several case series, the large clinical RIM trial was undertaken [9] . In this study, 200 patients with refractory myositis (76 with PM, 76 with DM and 48 with JDM) were randomized to receive different regimens of RTX (two infusions at baseline or 8 weeks later). Refractory disease was defined as the failure of steroids and at least one immunosuppressive agent for a duration of at least 3 months treatment with the agent at a known effective dose. Although the group treated with RTX at onset did not improve significantly earlier than the group treated after a delay of 8 weeks (the primary end point), the majority of patients (83%) responded to RTX treatment, and a significant steroid-sparing effect was reported. Twenty-six serious adverse effects attributed to RTX therapy were observed, most of which were infections. In an accompanying editorial [57] , De Visser has described several limitations of the RIM study, mainly concerning the trial design. The power calculation was based on the postulated effect of RTX by 8 weeks, but an improvement was observed only after 20 weeks. The selection of an 8-week placebo phase was based on ethical considerations, but it was felt to be too short to detect a significant difference. Moreover, the core set of measures used was only partially validated. The selection of patients was performed according to the Bohan and Peter criteria [58] , and not with the most recent classification criteria [59] . For these reasons, the trial was probably not powered to detect an effect of the RTX treatment. Thus, while formally negative, the results of the RIM trial did give some support for the idea that RTX might be an effective treatment strategy in IIM.
In this review, we have observed a rate of therapeutic response to RTX of 78.3% (359/458 patients). To avoid a publication bias of case reports and small series, we subsequently excluded the case series of three or less from the calculation for the response rate. We found that, excluding these studies, 323 out of 420 patients responded to RTX treatment (76.9%). Interestingly, the majority of patients with myositis-specific autoantibodies (MSA) positivity achieved a good response, often with long-term remission (512 months). MSAs are disease markers closely associated with clinical subsets of IIM and they are found in 3050% of the patients with myositis [33] . The presence of these antibodies seems to predict a better response to B celldepleting therapies. Nalotto et al. [45] described a significant improvement in five out of six patients after RTX treatment. Antibody positivity was found in each responder, supporting the idea of a role for B cells in the pathogenesis of myositis. In a post hoc analysis of the subgroups in the RIM trial, Aggarwal et al. [60] investigated predictors of clinical improvement in PM/DM patients treated with RTX. The positivity of a myositis autoantibody was the major predictive factor of clinical improvement following B celldepletion therapy (2-to 3-fold higher chances of improvement as compared with the negative autoantibody group). Among the autoantibody-positive subset, patients with antiMi-2 or antiJo1 demonstrated greater improvement than patients with other MSAs (such as anti-signal recognition particle, antiTIF-1g and anti-MJ), who showed only a non-significant trend to faster time to response than antibody-negative patients (hazard ratio: 1.4).
Interestingly, in many reports, levels of Jo-1 antibodies did not correlate with the disease course or relapse, but seem to remain stable [1012, 15, 31] . The probable explanation is that long-lived plasma cells producing autoantibodies are CD20-negative and are not affected by RTX. Moreover, the effect of RTX may be only partially related to blockade of the antibody production. RTX treatment may have an influence on other cells of the immune system and may normalize autoreactive T cells and reestablish the immune homeostasis [60] .
The measurement of autoantibodies is also useful for predicting clinical manifestations and prognosis in patients with myositis. Anti-melanoma differentiationassociated gene 5 and anti-aminoacyl-tRNA synthetase antibodies are associated with a high risk of ILD, which is one of the most common causes of mortality in IIM patients [61] . However, ILD associated with these two antibodies showed different clinical courses and therapeutic responsiveness. Anti-melanoma differentiationassociated gene 5positive patients mostly developed acute, progressive ILD that had a more severe course and was more refractory to treatment [61] . These findings suggest that MSAs, which are important prognostic markers, may also predict RTX response in IIM.
According to aetiopathological criteria, targeting B cells may also be potentially useful in treating DM, which is classically considered a humoral-mediated disorder [62] . Paradoxically, a better response to B celldepleting therapy has been observed in patients with predominant muscle involvement than in those with DM and skin disease. In our review, 52.1% of patients with skin lesions responded to RTX, but we noted a high frequency of www.rheumatology.oxfordjournals.org relapse (48.6%; 18/37 patients). In a subgroup of subjects enrolled in the RIM trial [53] , muscle assessment was more responsive than cutaneous measures to RTX treatment. Moreover, RTX was ineffective in treating skin manifestations in eight patients reported by Chung et al. [17] . Photosensitive heliotrope rash and violaceous poikiloderma seem to be the DM manifestations more sensitive to RTX [16] . In contrast, paraneoplastic skin lesions and calcinosis were often refractory to B celldepleting therapy [34, 29] .
In addition, the JDM group showed a more rapid improvement in the trial compared with either adult DM or PM group [9] . However, this difference was not statistically significant between the treatment arms, possibly related to the too small sample size [63] .
These findings confirm the complexity of the disease and suggest that the depletion of B lymphocytes may be a useful therapeutic advance, but that it is not going to be a cure for IIM. Furthermore, in some patients, RTX therapy did not lead to a clinical improvement. Thus, it is still unclear what role B cells have in the pathogenesis of myositis and whether MSAs are pathogenic and directly involved in muscle damage or are an epiphenomenon. Non-immune mechanisms may also be involved in IIM pathology. In this context, evidence for a degenerative process in IBM is of interest. The complexity of IIM pathogenesis necessitates further mechanistic studies of RTX, particularly in treatment-naïve patients, in order to provide a more personalized therapeutic approach.
In conclusion, although it is not yet possible to make definite recommendations, the global analysis of all cases in the literature support the off-label use of RTX in some patients with refractory myositis. The lack of validated criteria for evaluating clinical response and the concomitant use of immunosuppressive drugs limit our ability to determine the specific role of B celldepletion therapy. Further studies of RTX in myositis are needed, particularly in treatment-naïve patients.
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